Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Proton therapy as repeat radiation for head and neck cancer that has returned

Follows adults given proton therapy for head and neck cancer recurring in previously irradiated areas.

Plain-language title generated from the registry record
Registry title: REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors

Key facts

Where
Rozzano, ItalySee the site

Where in Italy

  • IRCCS Humanitas Research HospitalRozzano, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Istituto Clinico Humanitas
Trial code
NCT07635641
Record updated
9 June 2026
Original description
Some patients with head and neck cancer may develop a tumor recurrence in an area that has already been treated with radiotherapy. In these situations, surgery is not always possible, and giving radiotherapy again can be challenging because nearby healthy tissues and organs may already have received high radiation doses.Read full original descriptionShow less

REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors

Some patients with head and neck cancer may develop a tumor recurrence in an area that has already been treated with radiotherapy. In these situations, surgery is not always possible, and giving radiotherapy again can be challenging because nearby healthy tissues and organs may already have received high radiation doses.

The REPROton-HN study is evaluating the use of proton therapy for these patients. Proton therapy is a type of radiation treatment that can deliver radiation more precisely to the tumor while reducing exposure to surrounding healthy tissues.

The aim of the study is to better understand how safe and effective proton therapy is when used as a second course of radiation treatment. Researchers will monitor side effects, tumor control, survival, and patients' quality of life. The results may help improve treatment planning and identify which patients are most likely to benefit from proton therapy in the future.

Inclusion: ≥ 18 years old; ECOG 0-2; Pathologically and or radiologically confirmed head and neck cancer recurrence; Indication for proton therapy; Written informed consent for REPRO-HN according to applicable legal and ethical requirements by the end of radiotherapy treatment.

Exclusion: Age < 18 years old; ECOG>3; Life expectancy < 3 months; Inability to provide informed consent.

ClinicalTrials.gov NCT07635641